Janney Montgomery Scott’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$572K Buy
6,697
+1,519
+29% +$158K ﹤0.01% 2295
2026
Q2
$606K Buy
5,178
+2,278
+79% +$229K ﹤0.01% 2266
2026
Q1
$268K Sell
2,900
-300
-9% -$28.2K ﹤0.01% 2463
2025
Q4
$253K Buy
3,200
+200
+7% +$14.4K ﹤0.01% 2664
2025
Q3
$220K Buy
+3,000
New +$191K ﹤0.01% 2682
2024
Q2
– Sell
-14,812
Closed -$372K – 2737
2024
Q1
$372K Sell
14,812
-9,288
-39% -$255K ﹤0.01% 2196
2023
Q4
$711K Buy
24,100
+5,175
+27% +$157K ﹤0.01% 1663
2023
Q3
$598K Buy
18,925
+950
+5% +$26K ﹤0.01% 1649
2023
Q2
$465K Buy
17,975
+100
+0.6% +$2.66K ﹤0.01% 1913
2023
Q1
$429K Sell
17,875
-450
-2% -$10.3K ﹤0.01% 1814
2022
Q4
$357K Sell
18,325
-1,100
-6% -$21.7K ﹤0.01% 1990
2022
Q3
$408K Buy
19,425
+2,700
+16% +$65K ﹤0.01% 1822
2022
Q2
$308K Buy
16,725
+3,100
+23% +$73.1K ﹤0.01% 1901
2022
Q1
$300K Buy
+13,625
New +$278K ﹤0.01% 1880

Other funds holding MIRM

Janney Montgomery Scott's MIRM Position: Q3 2026 in Review

Janney Montgomery Scott increased its Mirum Pharmaceuticals (MIRM) stake by 29% in Q3 2026, buying an estimated $158K and bringing the position to 6,697 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #2295.

Janney Montgomery Scott first reported a position in MIRM in Q1 2022 and has held it in 14 quarters since. The position peaked at $711K in Q4 2023. 317 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

  • Janney Montgomery Scott held 6,697 shares of Mirum Pharmaceuticals worth $572K as of Q3 2026.
  • Janney Montgomery Scott bought 1,519 Mirum Pharmaceuticals shares in Q3 2026, an estimated $158K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q3 2026, its #2295 holding.
  • Janney Montgomery Scott first reported a position in Mirum Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Janney Montgomery Scott's Mirum Pharmaceuticals position peaked at $711K in Q4 2023.
  • 317 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Janney Montgomery Scott's 13F filing for Q3 2026, filed 12 Nov 2026.